Repligen Corporation — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2014. Repligen develops and sells bioprocessing products for life-sciences and biopharmaceutical manufacturers, with operations in the United States and Sweden. It reported as one operating segment.
Financial performance and position
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Total revenue | $15.55m | $17.51m | $31.88m | $33.96m |
| Product revenue | $15.55m | $13.01m | $29.89m | $24.95m |
| Operating income | $3.11m | $6.10m | $8.41m | $9.65m |
| Net income | $2.83m | $4.54m | $7.10m | $6.88m |
| Diluted EPS | $0.09 | $0.14 | $0.22 | $0.21 |
| Operating cash flow | Not presented by quarter | $10.32m | $12.39m |
- Product revenue increased 19% in Q2 and 20% in the first half, reflecting higher key-customer orders and the addition of Refine Technology. Total revenue fell 11% and 6%, respectively, mainly because Bristol-Myers Squibb Orencia royalties had ended after December 31, 2013. The 2014 first-half total also included $2.0m from the BioMarin asset sale.
- Q2 operating margin was approximately 20.0% versus 34.9% a year earlier; first-half operating margin was 26.4% versus 28.4%. The mix shift and absence of prior-year royalty revenue limit comparability. Product gross margin was approximately 57.1% in Q2 and 56.5% for the first half; management cautioned that product gross margins may decline during the rest of 2014 due to production volume, shipments, and mix.
- At June 30, cash and cash equivalents were $33.76m and marketable securities were $28.17m, totaling $61.92m, versus $73.84m at year-end 2013. Working capital was $65.04m, down from $75.05m. Current assets were $73.86m and current liabilities $8.82m. The balance sheet reported no borrowings or other conventional debt.
- First-half investing cash outflow was $16.85m, primarily reflecting the $21.24m cash payment for Refine, partly offset by net securities redemptions. Cash declined by $6.07m during the period. Total assets were $129.05m and stockholders’ equity $115.56m at June 30.
Material changes, outlook, and risks
- Refine acquisition: Closed June 2 for the ATF System business, adding a complementary bioprocessing product and expanding direct sales reach. Consideration included $21.24m cash, 215,285 shares valued at $4.0m, and $1.4m initial fair value for contingent consideration. Potential sales-target payments total up to $10.9m, with up to a further $7.5m tied to certain patent-dispute proceeds. Purchase-price allocation was preliminary. Refine contributed $466,000 revenue and $56,000 net income after acquisition through June 30.
- Management outlook: Repligen expected remaining-2014 R&D and SG&A expenses at levels similar to the first half, while expanding customer-facing activity and investing in bioprocessing products. It believed existing cash was adequate for at least 24 months absent further acquisitions. No specific revenue or earnings guidance was provided. Management warned that quarterly product orders can fluctuate and that margins may weaken.
- Other arrangements: BioMarin paid $2m upfront for Repligen’s HDACi portfolio; Repligen may receive up to $160m in future milestones plus royalties, contingent on development and commercial events. These amounts are not assured. The Pfizer SMA program remained licensed, with Repligen’s transition obligations completed in 2013. Development of RG1068 would depend on third-party support following FDA requests for additional trial data.
- Concentration and operating risks: Bioprocessing Customer A represented 48% of Q2 revenue and Customer B 22%; Customer A accounted for 33% of trade and other receivables. Refine relies on a limited supplier base, including an exclusive supplier for certain consumables. Integration, customer adoption, acquired intangible-asset impairment, supply continuity, and revenue variability are material risks.
- Liquidity commitments and other exposures: An amended lease adds 19,900 square feet and approximately $361,000 annualized rent, with an increased $450,000 security deposit. Reported fixed obligations and commitments totaled $21.85m, including operating leases, purchase obligations, and contingent consideration. The company disclosed foreign-currency exposure without hedging; a 100-basis-point interest-rate decrease was estimated to reduce investment fair value by about $241,000.
- Disclosure controls were considered effective. The Refine business, about 21% of reported assets, was excluded from the current-period internal-control assessment under the SEC guidance for recently acquired businesses. The filing reported no material legal proceedings known to management and no material changes to previously disclosed risk factors other than Refine-related risks.
Important facts for investors to verify
- Whether growth in recurring bioprocessing product sales can offset the permanent loss of Orencia royalties and the effect of lumpy customer orders.
- Refine’s post-acquisition sales, customer acceptance, supplier continuity, integration progress, and any changes to the preliminary purchase-price allocation or contingent payments.
- Actual gross-margin trends, particularly against management’s warning about 2014 production volume, shipments, and product mix.
- Whether BioMarin milestones and royalties become payable; they are contingent and are not included as assured future revenue.
- Cash use, acquisition plans, lease commitments, and the effect of customer and geographic concentration on liquidity and results.